We at SGS-Quay Pharma develop Drug Delivery Systems (DDS) with a passion gaining tremendous satisfaction from successfully developing for you the very best bespoke DDS for your Drug Substance, thereby bringing you effectively into the clinic & delivering the best possible clinical results.

We are a leading CDMO priding ourselves in our scientific rigor & knowledge to build a complete understanding of your drug’s mechanism & potential efficacy while taking a practical approach to finding a robust solution to design & develop DDSs that have taken many projects from early-stage development to commercial manufacture. We apply solid project management, technical expertise & a consultancy approach working as a dedicated, proactive part of your team to take your project quickly & cost-effectively to where you aspire to be in the clinic under IP-free conditions that won’t tie you into a platform technology or to particular manufacturers.

We appreciate that during development, time is precious & there are associated pressures that accompany time constraints to get to market ever quicker & realize the potential of your asset. With over 20 years of experience in supporting clients through the development continuum, with SGS-Quay Pharma you will minimize your risks while continuing to progress at a pace to maximize your benefits as we build a customized development pathway based on scientific first principles.

We develop formulations for most dosage forms & all types of molecules, large, small & controlled substances, & are expert in developing dosage forms for products where the bioavailability of the active requires enhancement or where the release of the drug requires targeting or modifying.

We are a leading innovator in the pharma-grade live-biotherapeutic/microbial space, fully licensed to handle BSL-1 & 2 strains as well as genetically modified microorganisms. We work with fastidious anaerobes, multi-species consortia, spores, bacteriophages, viral vectors & microbially derived recombinant peptides; a diversity of capabilities that requires a broad range of expertise, analytical techniques, operational flexibility & handling. We typically provide advice to each client on the best way forward for their project.

We develop the analytics, validate the methods, perform QC testing, monitor the stability, perform solid-state analysis & test for extractables & leachables. With over two hundred scientists & technicians at our UK & US facilities, we conduct manufacturing under FDA/EMA/MHRA GMP certified conditions, & on completion of your project we provide a Certificate of GMP Conformance & a QP release.

For your early phase clinical trials, we possess a Phase 1 Patient Unit that has experience in numerous therapeutic areas; Oncology, Cardiology, Dermatology, Endocrinology, Geriatrics, Gastroenterology, Hepatology, Neurology, Orthopedics, Pneumology & Vascular Surgery, supporting enrolment & study conduct & providing access to a wide range of patient populations.

So, if you are seeking to entrust your treasured project with a reliable CDMO that takes a consultancy approach to develop a bespoke DDS to create your desired target product profile (TPP) using an IP free model that frees you of any consideration for a royalty baggage – Come talk to us even before you decide on your preferred dosage form, and we will discuss with you the alternatives.
We hold a track record of over three hundred projects successfully developed & delivered.
We look forward to meeting you at booth # 46.